INS and Hyperglycemia: The currently increasing prevalence of T2DM is a considerable global concern in healthcare that will rise to approximately 642 million by 2040 (Al‐Lawati, 2017).T2DM is a chronic metabolic syndrome, characterized by impaired either insulin secretion or resistance to actions of insulin, or both, resulting in hyperglycemia (Stumvoll et al., 2005).